Magnetic Resonance Imaging: Utility as a Molecular Imaging Modality

Current Topics in Developmental Biology

Volumn 70, Issue , 2005, Pages 1-33

  Basilion, James P ^a   Yeon, Susan ^b   Botnar, René ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BREATHING; GENETIC PROCEDURES; HEART; HUMAN; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; TIME;

ANIMALS; HEART; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR PROBE TECHNIQUES; RESPIRATION; TIME FACTORS;

EID: 33645915760     PISSN: 00702153     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0070-2153(05)70001-6     Document Type: Review

References (85)

1. Aime S., Cabella C., Colombatto S., Geninatti Crich S., Gianolio E., and Maggioni F. Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations. J. Magn. Reson. Imaging 16 (2002) 394-406
2. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson Jr. J., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., and Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
3. Allen M.J., and Meade T.J. Magnetic resonance contrast agents for medical and molecular imaging. Met. Ions Biol. Syst. 42 (2004) 1-38
4. Anderson S.A., Rader R.K., Westlin W.F., Null C., Jackson D., Lanza G.M., Wickline S.A., and Kotyk J.J. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn. Reson. Med. 44 (2000) 433-439
5. Artemov D. Molecular magnetic resonance imaging with targeted contrast agents. J. Cell. Biochem. 90 (2003) 518-524
6. Artemov D., Mori N., Okollie B., and Bhujwalla Z.M. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn. Reson. Med. 49 (2003) 403-408
7. Artemov D., Mori N., Ravi R., and Bhujwalla Z.M. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 63 (2003) 2723-2727
8. Ben-Dor A., Bruhn L., Friedman N., Nachman I., Schummer M., and Yakhini Z. Tissue classification with gene expression profiles. J. Comput. Biol. 7 (2000) 559-583
9. Bogdanov Jr. A., Matuszewski L., Bremer C., Petrovsky A., and Weissleder R. Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets. Mol. Imaging 1 (2002) 16-23
10. Botnar R.M., Buecker A., Wiethoff A.J., Parsons Jr. E.C., Katoh M., Katsimaglis G., Weisskoff R.M., Lauffer R.B., Graham P.B., Gunther R.W., Manning W.J., and Spuentrup E. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 110 (2004) 1463-1466
11. Botnar R.M., Perez A.S., Witte S., Wiethoff A.J., Laredo J., Hamilton J., Quist W., Parsons Jr. E.C., Vaidya A., Kolodziej A., Barrett J.A., Graham P.B., Weisskoff R.M., Manning W.J., and Johnstone M.T. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 109 (2004) 2023-2029
12. Butte A.J., Tamayo P., Slonim D., Golub T.R., and Kohane I.S. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc. Natl. Acad. Sci. USA 97 (2000) 12182-12186
13. Caravan P., Ellison J.J., McMurry T.J., and Lauffer R.B. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem. Rev. 99 (1999) 2293-2352
14. Caravan P., Greenwood J.M., Welch J.T., and Franklin S.J. Gadolinium-binding helix-turn-helix peptides: DNA-dependent MRI contrast agents. Chem. Commun. (Camb.) 20 (2003) 2574-2575
15. Chen J.W., Pham W., Weissleder R., and Bogdanov Jr. A. Human myeloperoxidase: A potential target for molecular MR imaging in atherosclerosis. Magn. Reson. Med. 52 (2004) 1021-1028
16. Clare S., Francis S., Morris P.G., and Bowtell R. Single-shot T2(*) measurement to establish optimum echo time for fMRI: Studies of the visual, motor, and auditory cortices at 3.0 T. Magn. Reson. Med. 45 (2001) 930-933
17. Dahnke H., Weiss S., and Schaeffter T. Simultaneous T2* mapping and anatomical imaging using a fast radial multi-gradient-echo acquisition. Paper presented at: ISMRM (2004), International Society for Magnetic Resonance Imaging, Kyoto
18. Dousset V., Delalande C., Ballarino L., Quesson B., Seilhan D., Coussemacq M., Thiaudiere E., Brochet B., Canioni P., and Caille J.M. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn. Reson. Med. 41 (1999) 329-333
19. Enochs W.S., Petherick P., Bogdanova A., Mohr U., and Weissleder R. Paramagnetic metal scavenging by melanin: MR imaging. Radiology 204 (1997) 417-423
20. Ferrucci J.T., and Stark D.D. Iron oxide-enhanced MR imaging of the liver and spleen: Review of the first 5 years. AJR Am. J. Roentgenol. 155 (1990) 943-950
21. Fischer S.E., Wickline S.A., and Lorenz C.H. Novel real-time R-wave detection algorithm based on the vectorcardiogram for accurate gated magnetic resonance acquisitions. Magn. Reson. Med. 42 (1999) 361-370
22. Flacke S., Fischer S., Scott M.J., Fuhrhop R.J., Allen J.S., McLean M., Winter P., Sicard G.A., Gaffney P.J., Wickline S.A., and Lanza G.M. Novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation 104 (2001) 1280-1285
23. Funovics M.A., Kapeller B., Hoeller C., Su H.S., Kunstfeld R., Puig S., and Macfelda K. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn. Reson. Imaging 22 (2004) 843-850
24. Gayed I., Vu T., Iyer R., Johnson M., Macapinlac H., Swanston N., and Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J. Nucl. Med. 45 (2004) 17-21
25. Goerres G.W., Stupp R., Barghouth G., Hany T.F., Pestalozzi B., Dizendorf E., Schnyder P., Luthi F., Von Schulthess G.K., and Leyvraz S. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: Long-term outcome of treatment with imatinib mesylate. Eur. J. Nucl. Med. Mol. Imaging 32 (2004) 153-162
26. Gohr-Rosenthal S., Schmitt-Willich H., Ebert W., and Conrad J. The demonstration of human tumors on nude mice using gadolinium-labelled monoclonal antibodies for magnetic resonance imaging. Invest. Radiol. 28 (1993) 789-795
27. Golub T.R. Genome-wide views of cancer. N. Engl. J. Med. 344 (2001) 601-602
28. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., and Lander E.S. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286 (1999) 531-537
29. Grimm J., Perez J.M., Josephson L., and Weissleder R. Novel nanosensors for rapid analysis of telomerase activity. Cancer Res. 64 (2004) 639-643
30. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., de la Rosette J., and Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348 (2003) 2491-2499
31. Henderson E., McKinnon G., Lee T.Y., and Rutt B.K. A fast 3D look-locker method for volumetric T1 mapping. Magn. Reson. Imaging 17 (1999) 1163-1171
32. Hogemann D., and Basilion J.P. "Seeing inside the body": MR Imaging of gene expression. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) 400-408
33. Hogemann D., Josephson L., Weissleder R., and Basilion J.P. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug. Chem. 11 (2000) 941-946
34. Hogemann D., Ntziachristos V., Josephson L., and Weissleder R. High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjug. Chem. 13 (2002) 116-121
35. Hogemann-Savellano D., Bos E., Blondet C., Sato F., Abe T., Josephson L., Weissleder R., Gaudet J., Sgroi D., Peters P.J., and Basilion J.P. The transferrin receptor: A potential molecular imaging marker for human cancer. Neoplasia 5 (2003) 495-506
36. Ichikawa T., Hogemann D., Saeki Y., Tyminski E., Terada K., Weissleder R., Chiocca E.A., and Basilion J.P. MRI of transgene expression: Correlation to therapeutic gene expression. Neoplasia 4 (2002) 523-530
37. Jacobs A., Tjuvajev J.G., Dubrovin M., Akhurst T., Balatoni J., Beattie B., Joshi R., Finn R., Larson S.M., Herrlinger U., Pechan P.A., Chiocca E.A., Breakefield X.O., and Blasberg R.G. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res. 61 (2001) 2983-2995
38. Jacobs A., Voges J., Reszka R., Lercher M., Gossmann A., Kracht L., Kaestle C., Wagner R., Wienhard K., and Heiss W.D. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358 (2001) 727-729
39. Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Med. Klin (Munich) 97 Suppl. 1 (2002) 28-30
40. Johansson L.O., Bjornerud A., Ahlstrom H.K., Ladd D.L., and Fujii D.K. A targeted contrast agent for magnetic resonance imaging of thrombus: Implications of spatial resolution. J. Magn. Reson. Imaging 13 (2001) 615-618
41. Johnson G.A., Benveniste H., Black R.D., Hedlund L.W., Maronpot R.R., and Smith B.R. Histology by magnetic resonance microscopy. Magn. Reson. Quarterly 9 (1993) 1-30
42. Kang H.W., Josephson L., Petrovsky A., Weissleder R., and Bogdanov Jr. A. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug. Chem. 13 (2002) 122-127
43. Kim Y.S., Konoplev S.N., Montemurro F., Hoy E., Smith T.L., Rondon G., Champlin R.E., Sahin A.A., and Ueno N.T. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin. Cancer Res. 7 (2001) 4008-4012
44. Kramer C.M., Cerilli L.A., Hagspiel K., Di Maria J.M., Epstein F.H., and Kern J.A. Magnetic resonance imaging identifies the fibrous cap in atherosclerotic abdominal aortic aneurysm. Circulation 109 (2004) 1016-1021
45. Laniado M., Weinmann H.J., Schorner W., Felix R., and Speck U. First use of GdDTPA/dimeglumine in man. Physiol. Chem. Phys. Med. NMR. 16 (1984) 157-165
46. Laxman B., Hall D.E., Bhojani M.S., Hamstra D.A., Chenevert T.L., Ross B.D., and Rehemtulla A. Noninvasive real-time imaging of apoptosis. Proc. Natl. Acad. Sci. USA 99 (2002) 16551-16555
47. Lewin M., Carlesso N., Tung C.H., Tang X.W., Cory D., Scadden D.T., and Weissleder R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18 (2000) 410-414
48. Look D.C., and Locker D.R. Time saving in measurement of NMR and EPR relaxation times. Rev. Sci. Instrum. 41 (1970) 250-251
49. Louie A.Y., Huber M.M., Ahrens E.T., Rothbacher U., Moats R., Jacobs R.E., Fraser S.E., and Meade T.J. In vivo visualization of gene expression using magnetic resonance imaging. Nat. Biotechnol. 18 (2000) 321-325
50. Mahmood U., and Weissleder R. Near-infrared optical imaging of proteases in cancer. Mol. Cancer Ther. 2 (2003) 489-496
51. Messroghli D.R., Radjenovic A., Kozerke S., Higgins D.M., Sivananthan M.U., and Ridgway J.P. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn. Reson. Med. 52 (2004) 141-146
52. Moore A., Basilion J.P., Chiocca E.A., and Weissleder R. Measuring transferrin receptor gene expression by NMR imaging. Biochim. Biophys. Acta 1402 (1998) 239-249
53. Perez J.M., Josephson L., O'Loughlin T., Hogemann D., and Weissleder R. Magnetic relaxation switches capable of sensing molecular interactions. Nat. Biotechnol. 20 (2002) 816-820
54. Perez J.M., Josephson L., and Weissleder R. Use of magnetic nanoparticles as nanosensors to probe for molecular interactions. Chembiochem. 5 (2004) 261-264
55. Perez J.M., O'Loughin T., Simeone F.J., Weissleder R., and Josephson L. DNA-based magnetic nanoparticle assembly acts as a magnetic relaxation nanoswitch allowing screening of DNA-cleaving agents. J. Am. Chem. Soc. 124 (2002) 2856-2857
56. Perez J.M., Simeone F.J., Saeki Y., Josephson L., and Weissleder R. Viral-induced self-assembly of magnetic nanoparticles allows the detection of viral particles in biological media. J. Am. Chem. Soc. 125 (2003) 10192-10193
57. Perez J.M., Simeone F.J., Tsourkas A., Josephson L., and Weissleder R. Peroxidase Substrate Nanosensors fo MR Imaging. Nano Letters 4 (2004) 119-122
58. Pirko I., Johnson A., Ciric B., Gamez J., Macura S.I., Pease L.R., and Rodriguez M. In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodies. FASEB J. 18 (2004) 179-182
59. Reddy M.P., Reddy P., and Lilien D.L. F-18 FDG PET imaging in gastrointestinal stromal tumor. Clin. Nucl. Med. 28 (2003) 677-679
60. Reeder S.B., Faranesh A.Z., Boxerman J.L., and McVeigh E.R. In vivo measurement of T*2 and field inhomogeneity maps in the human heart at 1.5 T. Magn. Reson. Med. 39 (1998) 988-998
61. Rogers J., Lewis J., and Josephson L. Use of AMI-227 as an oral MR contrast agent. Magn. Reson. Imaging 12 (1994) 631-639
62. Schellenberger E.A., Hogemann D., Josephson L., and Weissleder R. Annexin V-CLIO: A nanoparticle for detecting apoptosis by MRI. Acad Radiol. 9 Suppl.2 (2002) S310-S311
63. Schellenberger E.A., Sosnovik D., Weissleder R., and Josephson L. Magneto/Optical annexin v, a multimodal protein. Bioconjug. Chem. 15 (2004) 1062-1067
64. Shen T.T., Bogdanov Jr. A., Bogdanova A., Poss K., Brady T.J., and Weissleder R. Bioconjug. Chem. 7 (1996) 311-316
65. Shen T., Weissleder R., Papisov M., Bogdanov Jr. A., and Brady T.J. Magnetically labeled secretin retains receptor affinity to pancreas acinar cells. Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties. Magn. Reson. Med. 29 (1993) 599-604
66. Shibata T., Weissleder R., Schaeffer B., Shen T., Papisov M., and Brady T. Tissue relaxivities and detectability of monocrystalline iron oxides. "Society of Magnetic Resonance in Medicine Annual Meeting," (1992) 1416, Berlin
67. Sirol M., Itskovich V.V., Mani V., Aguinaldo J.G., Fallon J.T., Misselwitz B., Weinmann H.J., Fuster V., Toussaint J.F., and Fayad Z.A. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 109 (2004) 2890-2896
68. Small W.C., Nelson R.C., and Bernardino M.E. Dual contrast enhancement of both T1- and T2-weighted sequences using ultrasmall superparamagnetic iron oxide. Magn. Reson. Imaging 11 (1993) 645-654
69. Smith B., Johnson G., Groman E., and Linney E. Magnetic resonance microscopy of mouse embryos. Proc. Natl. Acad. Sci. USA 91 (1994) 3530-3533
70. Stroobants S., Goeminne J., Seegers M., Dimitrijevic S., Dupont P., Nuyts J., Martens M., van den Borne B., Cole P., Sciot R., Dumez H., Silberman S., Mortelmans L., and van Oosterom A. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer 39 (2003) 2012-2020
71. Tempany C.M., and McNeil B.J. Advances in biomedical imaging. JAMA 285 (2001) 562-567
72. Van den Abbeele A.D., and Badawi R.D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur. J. Cancer 38 Suppl. 5 (2002) S60-S65
73. Wei J.S., Greer B.T., Westermann F., Steinberg S.M., Son C.G., Chen Q.R., Whiteford C.C., Bilke S., Krasnoselsky A.L., Cenacchi N., Catchpoole D., Berthold F., Schwab M., and Khan J. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 64 (2004) 6883-6891
74. Weinmann H.J., Ebert W., Misselwitz B., and Schmitt-Willich H. Tissue-specific MR contrast agents. Eur. J. Radiol. 46 (2003) 33-44
75. Weissleder R., Cheng H., Bogdanova A., and Bogdanov Jr. A. Magnetically labeled cells can be detected by MR imaging. J. Magn. Reson. Imaging 7 (1997) 258-263
76. Weissleder R., Elizondo G., Wittenberg J., Rabito C.A., Bengele H.H., and Josephson L. Ultrasmall superparamagnetic iron oxide: Characterization of a new class of contrast agents for MR imaging. Radiology 175 (1990) 489-493
77. Weissleder R., Moore A., Mahmood U., Bhorade R., Benveniste H., Chiocca E.A., and Basilion J.P. In vivo magnetic resonance imaging of transgene expression. Nat. Med. 6 (2000) 351-355
78. Weissleder R., and Ntziachristos V. Shedding light onto live molecular targets. Nat. Med. 9 (2003) 123-128
79. Weissleder R., Reimer P., Lee A.S., Wittenberg J., and Brady T.J. MR receptor imaging: Ultrasmall iron oxide particles targeted to asialoglycoprotein receptors. AJR Am. J. Roentgenol. 155 (1990) 1161-1167
80. Winter P.M., Caruthers S.D., Kassner A., Harris T.D., Chinen L.K., Allen J.S., Lacy E.K., Zhang H., Robertson J.D., Wickline S.A., and Lanza G.M. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 63 (2003) 5838-5843
81. Winter P.M., Morawski A.M., Caruthers S.D., Fuhrhop R.W., Zhang H., Williams T.A., Allen J.S., Lacy E.K., Robertson J.D., Lanza G.M., and Wickline S.A. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108 (2003) 2270-2274
82. Yeang C.H., Ramaswamy S., Tamayo P., Mukherjee S., Rifkin R.M., Angelo M., Reich M., Lander E., Mesirov J., and Golub T. Molecular classification of multiple tumor types. Bioinformatics 17 (2001) S316-S322
83. Yu X., Song S.K., Chen J., Scott M.J., Fuhrhop R.J., Hall C.S., Gaffney P.J., Wickline S.A., and Lanza E. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn. Reson. Med. 44 (2000) 867-872
84. Yuan C., Kerwin W.S., Ferguson M.S., Polissar N., Zhang S., Cai J., and Hatsukami T.S. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J. Magn. Reson. Imaging 15 (2002) 62-67
85. Zhao M., Beauregard D.A., Loizou L., Davletov B., and Brindle K.M. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat. Med. 7 (2001) 1241-1244